产品描述
This human PCSK9 ELISA kit employs the quantitative competitive enzyme immunoassay technique to measure the levels of human PCSK9 in different samples, including serum, plasma, or tissue homogenates. The enzyme-substrate chromogenic reaction is also used to amplify the signal and quantify the levels of the analyte through the intensity of the colored product. The color intensity negatively correlates with the amount of PCSK9 bound in the initial step.
PCSK9 is a serine protease that acts as a ligand for the low-density lipoprotein (LDL) and is a master participant in cholesterol homeostasis. PCSK9 upregulates LDL-cholesterol levels by binding to the LDLR and promoting its lysosomal degradation. PCSK9/LDLR binding also induces lysosomal degradation inside the cells thus resulting in a reduced LDLRexpression on the cell membrane. It is an important drug target due to its crucial role in lipid metabolism. High levels of PCSK9 are linked to enhanced increased atherosclerosis progress independent of LDL levels. PCSK9 also exerts pleiotropic roles in promoting inflammation in atherosclerosis.
别名
Convertase subtilisin/kexin type 9 preproprotein ELISA Kit; FH3 ELISA Kit; HCHOLA3 ELISA Kit; Hypercholesterolemia autosomal dominant 3 ELISA Kit; LDLCQ1 ELISA Kit; NARC 1 ELISA Kit; NARC-1 ELISA Kit; NARC1 ELISA Kit; Neural apoptosis regulated convertase 1 ELISA Kit; Neural apoptosis-regulated convertase 1 ELISA Kit; PC 9 ELISA Kit; PC9 ELISA Kit; PCSK 9 ELISA Kit; PCSK9 ELISA Kit; PCSK9_HUMAN ELISA Kit; Proprotein convertase 9 ELISA Kit; Proprotein convertase PC9 ELISA Kit; Proprotein convertase subtilisin/kexin type 9 ELISA Kit; PSEC0052 ELISA Kit; Subtilisin/kexin like protease PC9 ELISA Kit; Subtilisin/kexin-like protease PC9 ELISA Kit
缩写
PCSK9
Uniprot No
Q8NBP7
灵敏度
0.11 ng/mL
反应时间
1-5h
样本体积
50-100ul
检测波长
450 nm
研究领域
Metabolism
测定原理
quantitative
精密度
| Intra-assay Precision (Precision within an assay): CV%<8% |
|
|
|
| Three samples of known concentration were tested twenty times on one plate to assess. |
|
| Inter-assay Precision (Precision between assays): CV%<10% |
|
|
|
| Three samples of known concentration were tested in twenty assays to assess. |
|
|
| |
|
|
|
|
|
|
线性度
| To assess the linearity of the assay, samples were spiked with high concentrations of human PCSK9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. |
| |
Sample |
Serum(n=4) |
|
| 1:100 |
Average % |
87 |
|
| Range % |
84-90 |
|
| 1:200 |
Average % |
101 |
|
| Range % |
94-106 |
|
| 1:400 |
Average % |
92 |
|
| Range % |
88-97 |
|
| 1:800 |
Average % |
100 |
|
| Range % |
95-105 |
|
回收率
| The recovery of human PCSK9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. |
| Sample Type |
Average % Recovery |
Range |
|
| Serum (n=5) |
97 |
94-101 |
|
| EDTA plasma (n=4) |
101 |
97-103 |
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
标准曲线
| These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. |
| ng/ml |
OD1 |
OD2 |
Average |
|
|
| 30 |
0.090 |
0.086 |
0.088 |
|
|
| 15 |
0.228 |
0.241 |
0.235 |
|
|
| 7.5 |
0.351 |
0.372 |
0.362 |
|
|
| 3.75 |
0.573 |
0.598 |
0.586 |
|
|
| 1.8 |
0.927 |
0.936 |
0.932 |
|
|
| 0.9 |
1.607 |
1.632 |
1.620 |
|
|
| 0.45 |
1.907 |
1.876 |
1.892 |
|
|
| 0 |
2.655 |
2.615 |
2.635 |
|
|
|
货期
3-5 working days